Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-MIBG with Dinutuximab +/- Vorinostat in Neuroblastoma
NCT03332667Phase 1Completed
- Sponsor
- New Advances in Neuroblastoma Therapy
- Start
- Sep 2018
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Iobenguane I-131, dinutuximab and vorinostat in neuroblastoma (2 cohorts), sponsored by New Advances in Neuroblastoma Therapy. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose Cohort A at Day 56, Maximum Tolerated Dose / Recommended Phase 2 Dose Cohort B at Day 56 and 2 more. Started Sep 2018; status: completed.
02
Drugs
Iobenguane I-131dinutuximabvorinostat
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03332667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332667.